GENSCRIPT BIO(01548.HK): Legend Biotech Reports Positive Proof-of-Concept Clinical Data for In-vivo CD19/CD20 Dual-Target CAR-T Therapy LB2501

NewTimeSpace · 2026/06/14 20:33 · By Zeyu Wu

NewTimeSpace News: Genscript Biotech Corporation (01548.HK) announced that its associate company Legend Biotech presented the first proof-of-concept clinical data of LB2501, an investigational in-vivo CD19/CD20 dual-target CAR-T cell therapy, for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma at the 2026 EHA Annual Meeting. At higher dose levels, the overall response rate reached 100% and the complete response rate stood at 83.3%, with all responses sustained. No dose-limiting toxicity, serious adverse events or immune effector cell-associated neurotoxicity syndrome were reported.

NewTimeSpace News: Genscript Biotech Corporation (01548.HK) issued a voluntary announcement on June 14, 2026. It disclosed that Legend Biotech Corporation, its associate company, released a press release on June 14, 2026 (New York time), unveiling the first proof-of-concept clinical data of LB2501, an investigational in-vivo CD19/CD20 dual-target CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. The study results were presented during the Late-Breaking Abstract Session (Abstract No.: LB5006) of the 2026 European Hematology Association Annual Meeting.

In this ongoing Phase I study, a single infusion of LB2501 achieved dose-dependent expansion of in-vivo CAR-T cells without the need for lymphodepletion. At the higher dose level (DL2), LB2501 yielded an overall response rate of 100% (6/6) and a complete response rate of 83.3% (5/6). All responses remained sustained as of the data cutoff date.

LB2501 also demonstrated a favorable safety profile. No dose-limiting toxicity, serious adverse events, immune effector cell-associated neurotoxicity syndrome or deaths were reported.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

GENSCRIPT BIO 01548.HK Clinical Data